You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Inluriyo ™ (imlunestrant) tablets
200 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is Inluriyo® (imlunestrant) FDA approved?
The Food and Drug Administration (FDA) approved Inluriyo (imlunestrant) on September 25, 2025. On September 18, 2026, the FDA approved Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib).
Indications
Imlunestrant is an estrogen receptor antagonist indicated
- as monotherapy, for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy, and
- in combination with abemaciclib for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.1
Additional Information
More detailed information can be found on the US Food and Drug Administration website: www.fda.gov
Enclosed Prescribing Information
Enclosed Patient Information
Reference
1Inluriyo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: May 14, 2026